MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE LYMPHOBLASTIC LEUKEMIA: METHODS FOR DETECTION AND QUANTIFICATION.

Recently, the identification of minimal residual disease (MRD), also known as measurable residual disease, has seen significant advances driven by the evolving technological landscape in this field. Initially based on raw morphology, the field has since evolved to incorporate karyotyping, cytogenetics, flow cytometry, and other sensitive methods. This updated review discusses key technical considerations for successful MRD detection. We explore the correlation between the results obtained by flow cytometry and molecular genetic techniques.